Meeting NewsVideo

VIDEO: Lenvatinib-pembrolizumab shows promise in several cancer types

CHICAGO — Alton B. Kremer, MD, PhD, chief clinical officer and chief medical officer of the oncology business group at Eisai, spoke with HemOnc Today at ASCO Annual Meeting about key studies of agents in the company’s pipeline.

At ASCO, researchers presented data from studies designed to assess combination treatment with the multitargeted tyrosine kinase inhibitor lenvatinib (Lenvima, Eisai) and the anti-PD-1 monoclonal antibody pembrolizumab (Keytruda, Merck) for treatment of patients with renal cell carcinoma, endometrial cancer, head and neck cancer, and hepatocellular carcinoma.

Research into the combination for all four of these malignancies will move forward into advanced trials.

“The collaboration with Merck will lead to 11 potential registration studies across all of these tumors, as well as a new basket study with six new [tumor types] for which we haven’t studied the combination at all yet, so it’s really a broad program,” Kremer told HemOnc Today.

Kremer also highlighted three other “highest-priority new compounds” in early-stage development.

CHICAGO — Alton B. Kremer, MD, PhD, chief clinical officer and chief medical officer of the oncology business group at Eisai, spoke with HemOnc Today at ASCO Annual Meeting about key studies of agents in the company’s pipeline.

At ASCO, researchers presented data from studies designed to assess combination treatment with the multitargeted tyrosine kinase inhibitor lenvatinib (Lenvima, Eisai) and the anti-PD-1 monoclonal antibody pembrolizumab (Keytruda, Merck) for treatment of patients with renal cell carcinoma, endometrial cancer, head and neck cancer, and hepatocellular carcinoma.

Research into the combination for all four of these malignancies will move forward into advanced trials.

“The collaboration with Merck will lead to 11 potential registration studies across all of these tumors, as well as a new basket study with six new [tumor types] for which we haven’t studied the combination at all yet, so it’s really a broad program,” Kremer told HemOnc Today.

Kremer also highlighted three other “highest-priority new compounds” in early-stage development.

    See more from ASCO Annual Meeting